Evidence map›Paper›PMID 39954570›Full record

ArticleExperimental and molecular pathology2025

Diagnostic next-generation sequencing to detect MYD88 L265P in Lymphoplasmacytic lymphoma compared to ddPCR.

Lauren M Wainman, Guohong Huang, Donald C Green, Gregory J Tsongalis, Laura J Tafe, Wahab A Khan, Prabhjot Kaur, Parth S Shah, Jeremiah X Karrs

Abstract readComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Experimental and molecular pathology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Detection ofClinical case reports · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Lauren M WainmanDartmouth Hitchcock Medical Center, Lebanon, NH, USA.
Guohong HuangDartmouth Hitchcock Medical Center, Lebanon, NH, USA.
Donald C GreenDartmouth Hitchcock Medical Center, Lebanon, NH, USA.
Gregory J TsongalisDartmouth Hitchcock Medical Center, Lebanon, NH, USA.
Laura J TafeDartmouth Hitchcock Medical Center, Lebanon, NH, USA.
Wahab A KhanDartmouth Hitchcock Medical Center, Lebanon, NH, USA.
Prabhjot KaurDartmouth Hitchcock Medical Center, Lebanon, NH, USA.
Parth S ShahDartmouth Hitchcock Medical Center, Lebanon, NH, USA.
Jeremiah X KarrsDartmouth Hitchcock Medical Center, Lebanon, NH, USA. Electronic address: jeremiah.x.karrs@hitchcock.org.

Funding

Translational Engineering in Cancer (TEC)P30CA023108 · NCI · DARTMOUTH COLLEGE · PI Fred W Kolling IV · 1985 to 2026
$91.3M
NCI NIH HHS P30 CA023108
6 · The paper itself

Abstract

Lymphoplasmacytic lymphoma (LPL) is a B-cell lymphoproliferative disorder typically involving the bone marrow with infiltration by small lymphocytes and plasma cells. Studies have identified MYD88 L265P mutation as a diagnostic marker to distinguish LPL from other small B-cell lymphomas. Detection rates for this mutation have varied depending on the analytic methodology, with previous data suggesting that routine next-generation sequencing (NGS) does not demonstrate the required sensitivity to reliably detect MYD88 L265P. NGS has become part of routine clinical testing because it allows detection of variants across multiple genes. To study the utility of NGS in the detection of MYD88 L265P, we performed droplet digital PCR (ddPCR) and routine NGS on a cohort of 34 cases of lymphoid neoplasms (22 LPL, 4 CLL, 1 MCL, 1 MGUS, 2 plasma cell myeloma, and 4 negative bone marrow cases). We utilized manual review and BAMtools to assess MYD88 L265P in NGS cases. Limit of detection for ddPCR was determined to be 0.4 % variant allele frequency (VAF) with 10 ng DNA input. MYD88 L265P VAF detection by NGS and ddPCR was comparable down to 0.5 % VAF (R

Indexed as

High-Throughput Nucleotide SequencingMyeloid Differentiation Factor 88Polymerase Chain ReactionWaldenstrom MacroglobulinemiaBiomarkers, TumorFemaleHumansMaleMutationSensitivity and SpecificityBiomarkers, TumorMYD88 protein, humanMyeloid Differentiation Factor 88B-cell lymphomaddPCRLymphoplasmacytic lymphomaMolecularMolecular genetic pathologyMYD88NGSWaldenström macroglobulinemia

Identifiers

PMID39954570
PMCPMC12934476

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.